全文获取类型
收费全文 | 289186篇 |
免费 | 37587篇 |
国内免费 | 2519篇 |
专业分类
耳鼻咽喉 | 7374篇 |
儿科学 | 10083篇 |
妇产科学 | 5628篇 |
基础医学 | 24147篇 |
口腔科学 | 5992篇 |
临床医学 | 38061篇 |
内科学 | 72264篇 |
皮肤病学 | 11338篇 |
神经病学 | 28640篇 |
特种医学 | 12203篇 |
外科学 | 61898篇 |
综合类 | 870篇 |
现状与发展 | 72篇 |
一般理论 | 47篇 |
预防医学 | 14902篇 |
眼科学 | 6328篇 |
药学 | 10423篇 |
中国医学 | 207篇 |
肿瘤学 | 18815篇 |
出版年
2024年 | 774篇 |
2023年 | 5496篇 |
2022年 | 1641篇 |
2021年 | 4238篇 |
2020年 | 7069篇 |
2019年 | 3525篇 |
2018年 | 10278篇 |
2017年 | 9762篇 |
2016年 | 11597篇 |
2015年 | 11100篇 |
2014年 | 18434篇 |
2013年 | 20994篇 |
2012年 | 12560篇 |
2011年 | 13449篇 |
2010年 | 14764篇 |
2009年 | 17215篇 |
2008年 | 13862篇 |
2007年 | 12567篇 |
2006年 | 14705篇 |
2005年 | 11881篇 |
2004年 | 10700篇 |
2003年 | 9713篇 |
2002年 | 9727篇 |
2001年 | 9074篇 |
2000年 | 9728篇 |
1999年 | 6955篇 |
1998年 | 5123篇 |
1997年 | 4677篇 |
1996年 | 4283篇 |
1995年 | 3984篇 |
1994年 | 2706篇 |
1993年 | 2280篇 |
1992年 | 2179篇 |
1991年 | 2082篇 |
1990年 | 1709篇 |
1989年 | 1830篇 |
1988年 | 1587篇 |
1987年 | 1478篇 |
1986年 | 1433篇 |
1985年 | 1473篇 |
1984年 | 1250篇 |
1983年 | 1127篇 |
1982年 | 1130篇 |
1981年 | 973篇 |
1980年 | 889篇 |
1979年 | 831篇 |
1978年 | 793篇 |
1977年 | 892篇 |
1976年 | 661篇 |
1975年 | 703篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
51.
52.
53.
54.
55.
Claudia Gedlicka Gudrun Hager Martina Weissenböck Wilhelm Gedlicka Birgit Knerer Johannes Kornfehl Michael Formanek 《Journal of oral pathology & medicine》2006,35(8):472-478
BACKGROUND: 1Alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2) Vitamin D(3)] induces growth inhibition in squamous cell carcinoma (SCC) cell lines of the head and neck by arresting the cells in the G0/G1 phase of the cell cycle, probably due to an enhanced expression of p21, which could be demonstrated in other cell lines (JPPA, SCC9) before. In SCC25, a SCC cell line isolated from tongue, growth inhibition but no overexpression of p21 was detected. The retinoblastoma gene, as a direct target of G1 cyclin-CDK complexes, showed an obvious shift from the hyperphosphorylated to the hypophosphorylated form under 1,25(OH)(2)Vitamin D(3), which indicates that the growth inhibition takes place in the G0/G1 phase. To explore the possible pathway of growth inhibition in SCC25 we investigated other cell cycle inhibitors (p18, p19, p27). METHODS: Synchronized cells were treated with 1,25(OH)(2)Vitamin D(3) over 96 h. The cell cycle status and expression of cell cycle-regulating proteins was determined by fluorescence-activated cell sorting (FACS) and Western blotting. An overexpression of p18 in 1,25(OH)(2)Vitamin D(3) vs. ethanol-treated cells was determined until 30 h in SCC25. No influence was detectable on the expression of p27 and p19. CONCLUSION: One mechanism by which 1,25(OH)(2)Vitamin D(3) controls cell growth might be the upregulation of p21. As p21 was unsusceptible to 1,25(OH)(2)Vitamin D(3) in SCC25, other inhibiting proteins were necessary to be tested. The proven upregulation of p18 seems to be the responsible step for growth inhibition of 1,25(OH)(2)Vitamin D(3) in SCC25. 相似文献
56.
Prostatitis and male infertility are frequent disorders, and the role of prostatitis in male infertility has been under discussion for more than 30 years. Many researchers have shown relevant links between the two. Although a causal relationship has not been definitely demonstrated, increasing evidence shows that chronic prostatitis has a relevant negative impact on male fertility potential, at least in certain subgroups. In the following review, we focus on the present state of knowledge on the role of chronic prostatitis as an etiologic factor in male infertility. 相似文献
57.
J. Curtis Nickel MD 《Current Prostate Reports》2006,4(3):132-137
Medical therapy is currently the most popular treatment choice for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Because medical therapy of BPH-related LUTS is considered a life-long strategy, short- and long-term cost considerations should play a major role in therapeutic decision-making. The effectiveness in terms of long and short amelioration of symptoms, flow rate, and quality of life are well documented for 5α-blockers and 5α-reductase inhibitors as well as for the gold standard treatment for BPH, transurethral resection of the prostate and minimally invasive therapies. Short-and long-term safety concerns also are well documented for these various treatment options. On the contrary, short- and long-term costs have been less well studied and comparisons depend on the model or analyses undertaken in the few studies available. However, the economic studies based on prospective clinical trial data that have become available throughout the past several decades allow us to rationalize our use of α-blockers, 5α -reductase inhibitors, and combination therapy, taking into consideration age, severity of symptoms, prostate volume, prostate-specific antigen, and the differential response of the various medications (and combination) in selected patients. Based on current studies, 5α -blockers generally provide cost-effective therapy for most patients, whereas 5α-reductase therapy and combination therapy provide cost-effective treatment for patients with larger prostate glands or higher baseline prostate-specific antigen levels. 相似文献
58.
59.
INTRODUCTION: The clinical presentation of morphea varies from localized plaques to generalized eruptions. Its cause remains unknown and medical treatments have often proved unsatisfactory. Studies have previously shown that improvement of hypertrophic scars and fibrotic skin can be achieved with the use of a 585 nm pulsed dye laser (PDL). METHODS: A case of plaque-type morphea was treated with 585 nm pulsed dye laser irradiation at an average fluence of 5.0 J/cm2 at bimonthly time intervals. RESULTS: Marked clinical improvement as evidenced by improved pliability and skin coloration was seen after 4 successive PDL treatments. No side effects or complications were encountered. CONCLUSION: Pulsed dye laser therapy is a viable treatment option for morphea. The mechanism of its effect in this condition remains unknown. 相似文献
60.
Angiotensin Converting Enzyme Inhibitors: Animal Experiments Suggest a New Pharmacological Treatment for Alcohol Abuse in Humans 总被引:1,自引:0,他引:1
G. Spinosa MSc E. Perlanski Dipl Tech. F. H. H. Leenen MD R. B. Stewart MSc L. A. Grupp DSc 《Alcoholism, clinical and experimental research》1988,12(1):65-70
The prevalence of heavy alcohol consumption is a major problem of increasing proportions throughout the world. Although alcohol sensitizing drugs and more recently serotonin uptake inhibitors are drug interventions with some following, their long term beneficial consequences have yet to be demonstrated. In recent years, we have demonstrated that manipulating activity in the renin-angiotensin system will dramatically alter voluntary alcohol consumption in rats. Based on these findings, the present study evaluated the ability of a class of drugs known as the angiotensin converting enzyme inhibitors to reduce voluntary alcohol drinking in laboratory animals. These drugs prevent the conversion of angiotensin I to angiotensin II. They have been licensed for use in Europe and North America and are indicated in the treatment of hypertension. Our experiments showed that both captopril (Capoten, Squibb) and enalapril (Vasotec, Merck Sharpe & Dohme) can reduce alcohol drinking in both normotensive and hypertensive animals regardless of whether the pattern of intake is in a bout or of a less exaggerated nature. Furthermore, this change in alcohol intake can occur without concomitant changes in blood pressure, plasma renin activity, overall fluid balance, or the distribution and metabolism of alcohol. Taken together these findings suggest that the angiotensin converting enzyme inhibitors should be evaluated in a clinical setting for they may prove to be a useful new treatment or treatment adjunct for alcohol abuse in humans. 相似文献